Logo

Bristol-Myers Squibb to Divest Celgene's Otezla (apremilast) to Gain the US FTC's Approval on Celgene Acquisition

Share this

Bristol-Myers Squibb to Divest Celgene's Otezla (apremilast) to Gain the US FTC's Approval on Celgene Acquisition

Shots:

  • BMS plans to divest Otezla to address US Federal Trade Commission concern to close pending Celgene acquisition for $74B more quickly
  • In Jan’2019- BMS announced to acquire Celgene with its expected closing of the transaction in H2’19 or H1’20. The divestiture of Otezla will accelerate BMS post-closing deleveraging plans
  • Otezla is a PDE4 inhibitor- approved to treat moderate to severe plaque psoriasis and has generated a revenue of $1.6B in 2018

Click here to read full press release/ article | Ref: BMS | Image: SPJ News


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions